Previous studies focused on attaining low-density lipoprotein cholesterol (LDL-C) goals after lipid-modifying therapy (LMT), but data on achieving normal levels of triglyceride and high-density lipoprotein cholesterol (HDL-C) are limited. We reviewed medical records of patients initiated on LMT. High risk was defined as patients with coronary heart disease, diabetes, or 10-year Framingham risk >20%. Among 806 patients enrolled, 429 were at high risk. Prior to initiation of LMT, 66%, 35%, and 44% overall and 69%, 35%, and 45% in the high-risk group had elevated LDL-C, elevated triglyceride, and low HDL-C, respectively. After 12 months of LMT, 21%, 32%, and 39% overall and 26%, 25%, and 43% in the high-risk group still had elevated LDL-C, elevated triglyceride, and low HDL-C, respectively. Approximately 1 of 5 patients continued to experience elevated LDL-C coupled with elevated triglyceride and/or low HDL-C. In conclusion, a substantial proportion of patients initiated on LMT continued to have lipid abnormalities.
KannelWBCastelliWPGordonTMcNamaraPM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74(1):1–12.
2.
SarwarNDaneshJEiriksdottirG. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458.
3.
AssmannGSchulteHvon EckardsteinAHuangY. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(suppl):S11–S20.
4.
BaigentCBlackwellLEmbersonJ. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
5.
RidkerPMGenestJBoekholdtSM. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376(9738):333–339.
6.
ZhangLQiaoQTuomilehtoJ. DECODE/DECODA Study Group Distinct ethnic differences in lipid profiles across glucose categories. J Clin Endocrinol Metab. 2010;95(4):1793–1801.
7.
LiaoJK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99(3):410–414.
8.
MenottiALantiMKromhoutD. Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study. Eur J Cardiovasc Prev Rehabil. 2008;15(6):719–725.
9.
ZhangXPatelAHoribeH. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32(4):563–572.
10.
KhooKLTanHLiewYMDeslypereJPJanusE. Lipids and coronary heart disease in Asia. Atherosclerosis. 2003;169(1):1–10.
11.
FranceMWKwokSMcElduffPSeneviratneCJ. Ethnic trends in lipid tests in general practice. QJM. 2003;96(12):919–923.
12.
MisraAKhuranaL. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord. 2009;7(6):497–514.
13.
OkamuraTTanakaHMiyamatsuN. NIPPON DATA80 Research Group The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis. 2007;190(1):216–223.
14.
NakamuraHArakawaKItakuraH. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–1163.
15.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP).. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
16.
KimHSWuYLinSJ. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the return on expenditure achieved for lipid therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008;24(7):1951–1963.
17.
NitiyanantWSritaraPDeerochanawongCNgarmukosPKoanantakulB. Lipid treatment assessment project II in Thailand (LTAP-II Thailand). J Med Assoc Thai. 2008;91(6):836–845.
18.
HoKTChinKWNgKSAlemaoERajagopalanSYinD. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs. 2006;6(6):383–391.
19.
LeeKKLeeVWChanWK. Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study. Value Health. 2008;11(suppl 1):S91–S98.
20.
WuYF. The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35(5):420–427.
21.
GrundySMCleemanJIMerzCN. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education program adult treatment panel III guidelines. Circulation. 2004;110(2):227–239.
22.
NicholsGAAmbegaonkarBMSazonovVBrownJB. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol. 2009;104(12):1689–1694.
23.
PhatakHWentworthCSazonovVBurkeT. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis. 2009;202(1):225–233.
24.
WattsGFKarpeF. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97(5):350–356.
25.
GinsbergHNElamMBLovatoLC. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
26.
The AIM-HIGH Investigators.. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J. 2011;161(3):471–477 e472.
27.
GuytonJR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18(4):415–420.
28.
MiyaresMA. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann Pharmacother. 2011;45(1):84–94.
29.
KatcherHIHillAMLanfordJLYooJSKris-EthertonPM. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am. 2009;38(1):45–78.
